251 related articles for article (PubMed ID: 35680995)
1. Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari L; Balaguer-Roselló A; Montoro J; Greco R; Hernani R; Lupo-Stanghellini MT; Villalba M; Giglio F; Facal A; Lorentino F; Guerreiro M; Bruno A; Pérez A; Xue E; Clerici D; Piemontese S; Piñana JL; Sanz MÁ; Solano C; de la Rubia J; Ciceri F; Peccatori J; Sanz J
Bone Marrow Transplant; 2022 Sep; 57(9):1389-1398. PubMed ID: 35680995
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia.
Borovkova AS; Paina OV; Semenova EV; Bykova TA; Osipova AA; Slesarchuk OA; Kozhokar PV; Tsvetkova LA; Rakhmanova ZZ; Kozlov AV; Chukhlovin AB; Kazantsev IV; Estrina MA; Goloshchapov OV; Bondarenko SN; Moiseev IS; Kulagin AD; Zubarovskaya LS
Clin Transplant; 2024 Jan; 38(1):e15181. PubMed ID: 37922213
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
4. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Montoro J; Boumendil A; Finel H; Bramanti S; Castagna L; Blaise D; Dominietto A; Kulagin A; Yakoub-Agha I; Tbakhi A; Solano C; Giebel S; Gulbas Z; López Corral L; Pérez-Simón JA; Díez Martín JL; Sanz J; Farina L; Koc Y; Socié G; Arat M; Jurado M; Bermudez A; Labussière-Wallet H; Villalba M; Ciceri F; Martinez C; Nagler A; Sureda A; Glass B
Transplant Cell Ther; 2024 Feb; 30(2):210.e1-210.e14. PubMed ID: 38043802
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
7. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Swoboda R; Kulagin A; Labussière-Wallet H; Rovira M; Blaise D; Vydra J; Yakoub-Agha I; Choi G; Reményi P; Koc Y; Sanz J; Ciceri F; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):552-557. PubMed ID: 36823454
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J; Roldán E; Piñana JL; Barba P; Chorão P; Quintero A; Hernani R; Ortí G; Lorenzo JI; Balaguer-Roselló A; Salamero O; Fox L; Solves P; Gómez I; Guerreiro M; Hernández Boluda JC; Sanz G; Solano C; Sanz MÁ; Valcárcel D; Sanz J
Eur J Haematol; 2021 Jan; 106(1):114-125. PubMed ID: 33025625
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC.
Bailén R; Pascual-Cascón MJ; Guerreiro M; López-Corral L; Chinea A; Bermúdez A; Sampol A; Heras I; García-Torres E; Torres M; Roca JR; Herruzo B; Sanz J; Fonseca M; Herrera P; Colorado M; Bento L; López-Godino O; Martín-Calvo C; Fernández-Caldas P; Marcos-Jubilar M; Sánchez-Ortega I; Solano C; Noriega V; Humala K; Oarbeascoa G; Díez-Martín JL; Kwon M;
Transplant Cell Ther; 2022 Apr; 28(4):204.e1-204.e10. PubMed ID: 35108627
[TBL] [Abstract][Full Text] [Related]
11. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
Ruggeri A; Labopin M; Bacigalupo A; Afanasyev B; Cornelissen JJ; Elmaagacli A; Itälä-Remes M; Blaise D; Meijer E; Koc Y; Milpied N; Schouten HC; Kroeger N; Mohty M; Nagler A
J Hematol Oncol; 2018 Mar; 11(1):40. PubMed ID: 29544522
[TBL] [Abstract][Full Text] [Related]
13. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
14. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
15. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.
Shah MV; Saliba RM; Rondon G; Chen J; Soebbing D; Rus I; Alousi A; Oran B; Kebriaei P; Qazilbash M; Parmar S; Hosing C; Khouri IF; Popat UR; Champlin RE; Ciurea SO
Bone Marrow Transplant; 2019 Apr; 54(4):601-606. PubMed ID: 30337700
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT).
Ortí G; Gras L; Koster L; Kulagin A; Byrne J; Apperley JF; Halaburda K; Blau IW; Clark A; Kröger N; Griskevicius L; Carlson K; Collin M; Bloor A; Raiola AM; Blaise D; Aljurf M; López-Corral L; Sakellari I; Beguin Y; Wrobel T; de Rosa L; de Lavallade H; Hayden PJ; McLornan D; Chalandon Y; Yakoub-Agha I
Transplant Cell Ther; 2024 Jan; 30(1):93.e1-93.e12. PubMed ID: 37783337
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
[TBL] [Abstract][Full Text] [Related]
18. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
19. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
Montoro J; Piñana JL; Hernández-Boluda JC; Hernani R; Lorenzo I; Pérez A; Guerreiro M; Balaguer-Rosello A; Sanz GF; Carretero C; Albert E; Navarro D; Sanz MA; Solano C; Sanz J
Bone Marrow Transplant; 2020 Nov; 55(11):2147-2159. PubMed ID: 32371901
[TBL] [Abstract][Full Text] [Related]
20. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]